Safety and immunogenicity of ETHIORAB rabies vaccine

Journal of Vaccines and Vaccination

Volumn 4, Issue 6, 2013, Pages

  Hurisa, Birhanu ^a   Tegbaru, Belete ^a   Nolkes, Dagmar ^d   Mengesha, Abebe ^a   Kebede, Gezahegn ^a   Kerga, Sisay ^a   Adhanom, Amdemicael ^a   Godana, Alemayehu ^a   Nigussie, Dereje ^a   Newayesilasie, Bethelehem ^a   Gebrewold, Gashaw ^a   Bankovskiy, Denis ^b   Metlin, Artem ^c   Urga, Kelbessa ^a  

^a ETHIOPIAN PUBLIC HEALTH INSTITUTE   (Ethiopia)

^b Pokrov Plant of Biologics   (Russian Federation)

^c Federal Centre for Animal Health (FGI ARRIAH)   (Russian Federation)

^d HARAMAYA UNIVERSITY   (Ethiopia)

Author keywords

Dogs; ETHIORAB; Immunogenicity; Safety; Titer

Indexed keywords

EID: 84884753643     PISSN: None     EISSN: 21577560     Source Type: Journal    
DOI: 10.4172/2157-7560.1000195     Document Type: Article

References (32)

1. Rupprecht CE, Hanlon CA, Hemachudha T (2002) Rabies re-examined. Lancet Infect Dis 2: 327-343.
2. Knobel DL, Cleaveland S, Coleman PG, Fèvre EM, Meltzer MI, et al. (2005) Re-evaluating the burden of rabies in Africa and Asia. Bull World Health Organ 83: 360-368.
3. Yimer E, Newayesilassie B, Tefera G, Mekonen Y, Bogale Y, et al. (2001) Situation of Rabies in Ethiopia. A retrospective study 1990-2000. Ethiopian Health and Nutrition Research Institute.
4. Deresa A, Ali A, Beyene M, Newayesilasie B, Yimer E, et al. (2010) The status of rabies in Ethiopia: A retrospective record review. Ethiop J Health Dev 24: 105-112.
5. Mebatsion T, Cox JH, Frost JW (1992) Isolation and characterization of 115 street rabies virus isolates from Ethiopia by using monoclonal antibodies: identification of 2 isolates as Mokola and Lagos bat viruses. J Infect Dis 166: 972-977.
6. Wilde H, Tipkong P, Khawplod P (1999) Economic issues in postexposure rabies treatment. J Travel Med 6: 238-242.
7. Fooks AR, McElhinney LM, Brookes SM, Johnson N, Keene V, et al. (2002) Rabies antibody testing and the UK Pet Travel Scheme. Vet Rec 150: 428-430.
8. WHO (2004) Expert Consultation on Rabies, First report. Technical Report Series, No. 931.
9. Sureau P (1987) Rabies vaccine production in animal cell cultures. Adv Biochem Eng Biotechnol 34: 111-128.
10. WHO (1992) Expert Committee on Rabies, Eight report. Technical Report Series, No. 824.
11. Lodmell DL, Ewalt LC (2004) Rabies cell culture vaccines reconstituted and stored at 4 degrees C for 1 year prior to use protect mice against rabies virus. Vaccine 22: 3237-3239.
12. OIE Terrestrial Manual.
13. kissling RE, Reese DR (1963) Anti-rabies vaccine Of tissue culture origin. J Immunol 91: 362-368.
14. Willoughby RE Jr, Tieves KS, Hoffman GM, Ghanayem NS, Amlie-Lefond CM, et al. (2005) Survival after treatment of rabies with induction of coma. N Engl J Med 352: 2508-2514.
15. WHO (1981) Requirements for rabies vaccine for human use. WHO Expert Committee on Biological Standardization. Technical Report Series, No. 658, Annex 2.
16. Cliquet F, Aubert M, Sagné L (1998) Development of a fluorescent antibody virus neutralisation test (FAVN test) for the quantitation of rabies-neutralising antibody. J Immunol Methods 212: 79-87.
17. WHO (1994) Requirements for rabies vaccine for veterinary use (amendment 1992) WHO Expert Committeeon Biological Standardization. WHO Technical Report Series, No. 840), Annex 6.
18. Kallel H, Diouani MF, Loukil H, Trabelsi K, Snoussi MA, et al. (2006) Immunogenicity and efficacy of an in-house developed cell-culture derived veterinarian rabies vaccine. Vaccine 24: 4856-4862.
19. Sage G, Khawplod P, Wilde H, Lobaugh C, Hemachudha T, et al. (1993) Immune response to rabies vaccine in Alaskan dogs: failure to achieve a consistently protective antibody response. Trans R Soc Trop Med Hyg 87: 593-595.
20. Wang Y, Xiang Z, Pasquini S, Ertl HC (1998) Effect of passive immunization or maternally transferred immunity on the antibody response to a genetic vaccine to rabies virus. J Virol 72: 1790-1796.
21. Minke JM, Bouvet J, Cliquet F, Wasniewski M, Guiot AL, et al. (2009) Comparison of antibody responses after vaccination with two inactivated rabies vaccines. Vet Microbiol 133: 283-286.
22. Rio MB, Nancy B, Plebeian M, Beatriz P (2010) Safety and immunogenicity of rabies pre-and post-exposure intradermal regimens using Abhayrab, a purified vero cell rabies vaccine (PVRV) produced in India in healthy volunteers: towards greater affordability of rabies prophylaxis. Asian Biomedicine 4: 61-67.
23. Monaco F, Franchi PM, Lelli R (2006) Studies on an inactivated vaccine against rabies virus in domestic animals. Dev Biol (Basel) 125: 233-239.
24. Bahloul C, Ahmed SB, B'chir BI, Kharmachi H, Hayouniel A, et al. (2003) Post-exposure therapy in mice against experimental rabies: a single injection of DNA vaccine is as effective as five injections of cell culture-derived vaccine. Vaccine 22: 177-184.
25. Tepsumethanon W, Polsuwan C, Lumlertdaecha B, Khawplod P, Hemachudha T, et al. (1991) Immune response to rabies vaccine in Thai dogs: a preliminary report. Vaccine 9: 627-630.
26. WHO (2002) Rabies vaccines: WHO position paper. Wkly Epidemiol Rec 77: 109-120.
27. Cameron CM, Barnard BJ, Erasmus E, Botha WJ (1987) Antibody response in cattle to oil emulsion rabies and ephemeral fever vaccines. Onderstepoort J Vet Res 54: 157-158.
28. Dietzschold B, Faber M, Schnell MJ (2003) New approaches to the prevention and eradication of rabies. Expert Rev Vaccines 2: 399-406.
29. Hanlon CA, Kuzmin IV, Blanton JD, Weldon WC, Manangan JS, et al. (2005) Efficacy of rabies biologics against new lyssaviruses from Eurasia. Virus Res 111: 44-54.
30. Rupprecht CE, Hanlon CA, Blanton J, Manangan J, Morrill P, et al. (2005) Oral vaccination of dogs with recombinant rabies virus vaccines. Virus Res 111: 101-105.
31. Who (2007) Recommendations for inactivated rabies vaccine for human use produced in cell substrates and embryonated eggs. Technical Report Series.
32. Yusibov V, Modelska A, Steplewski K, Agadjanyan M, Weiner D, et al. (1997) Antigens produced in plants by infection with chimeric plant viruses immunize against rabies virus and HIV-1. Proc Natl Acad Sci USA 94: 5784-5788.